Acute Renal Failure (ARF) (Acute Kidney Injury) Treatment Pipeline Review H2 2016

WiseGuy Market Research Report

Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, August 30, 2016 /EINPresswire.com/ -- Summary

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2016’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury)
- The report reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics and enlists all their major and minor projects
- The report assesses Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/619296-acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h2-2016

Key points in table of content
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 11
Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 12
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 20
Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 22
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 23
A1M Pharma AB 23
Adrenomed AG 24
Am-Pharma B.V. 25
Angion Biomedica Corp. 26
Atox Bio Ltd. 27
Cellmid Limited 28
Complexa, Inc. 29
DiaMedica Inc. 30
Digna Biotech, S.L. 31
DURECT Corporation 32
F. Hoffmann-La Roche Ltd. 33
G1 Therapeutics, Inc. 34
Kringle Pharma, Inc. 35
NephroGenex, Inc. 36
NeuroVive Pharmaceutical AB 37
Noorik Biopharmaceuticals AG 38
Noxxon Pharma AG 39
Orion Oyj 40
ProMetic Life Sciences Inc. 41
Quark Pharmaceuticals, Inc. 42
SBI Pharmaceuticals Co., Ltd. 43
Spherium Biomed S.L. 44
STATegics, Inc. 45
Stealth BioTherapeutics Inc. 46
Thrasos Therapeutics Inc. 47
Torrent Pharmaceuticals Limited 48
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 49
Assessment by Monotherapy Products 49
Assessment by Combination Products 50
Assessment by Target 51
Assessment by Mechanism of Action 53
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
A1M-001 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
AB-103 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
adrecizumab - Drug Profile 64
Product Description 64
Mechanism Of Action 64

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=619296

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here